Overview
- TickerAVCRF1
- IndustryPharmaceutical Preparations1
- HeadquartersVancouver, Canada1
- Incorporated inBritish Columbia, Canada3
- Business address789 West Pender Street, Suite 810, Vancouver, A1 V6C 1H23
- Filer categoryNon-accelerated filer3
See how the biggest companies compare on our leaderboards
“Qualifying Transaction”, pursuant to the policies of the TSX Venture Exchange, is a transaction whereby a capital pool company:4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Financial statements
No quarterly figures reported.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 92.3K CAD9 | 1.3M CAD2 | 2.3M CAD2 | 2.9M CAD2 | ||||
| Gross profit | 0 CAD5 | -963 CAD6 | 14.5K CAD7 | 17.5K CAD8 | 30.5K CAD9 | 456.8K CAD2 | 1.2M CAD2 | 1.9M CAD2 |
| Interest | 21.1K CAD7 | |||||||
| Income before tax | -1.7M CAD9 | -817.9K CAD2 | -693.3K CAD2 | 129.0K CAD2 | ||||
| Net income | -1.3M CAD5 | -3.5M CAD6 | -1.9M CAD6 | -1.2M CAD6 | -1.7M CAD9 | -818.2K CAD2 | -701.2K CAD2 | -669.0K CAD2 |
| Earnings per share | -0 CAD/shares7 | -0 CAD/shares8 | -0 CAD/shares9 | -0 CAD/shares2 | -0 CAD/shares2 | -0 CAD/shares2 | ||
| Earnings per share (diluted) | -0 CAD/shares9 | -0 CAD/shares2 | -0 CAD/shares2 | -0 CAD/shares2 | ||||
| Shares (weighted, basic) | 92.6M shares9 | 97.9M shares2 | 99.6M shares2 | 100.3M shares2 | ||||
| Shares (weighted, diluted) | 97.9M shares2 | 99.6M shares2 | 100.3M shares2 |
No quarterly figures reported.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash | 559.7K CAD6 | 84.4K CAD7 | 13.8K CAD8 | 302.7K CAD9 | 2.0M CAD2 | 620.5K CAD2 | 276.6K CAD2 | 1.1M CAD2 |
| Receivables | 91.5K CAD8 | 770.4K CAD9 | 427.7K CAD2 | 419.6K CAD2 | ||||
| Inventory | 20.7K CAD2 | 507 CAD2 | ||||||
| Current assets | 2.2M CAD8 | 1.4M CAD9 | 773.6K CAD2 | 1.6M CAD2 | ||||
| Property, plant and equipment | 90.9K CAD8 | 1.1M CAD9 | 1.7M CAD2 | 656.4K CAD2 | ||||
| Total assets | 2.9M CAD10 | 1.2M CAD5 | 208.4K CAD6 | 440.1K CAD7 | 2.3M CAD8 | 2.6M CAD9 | 2.5M CAD2 | 2.3M CAD2 |
| Accounts payable | 44.5K CAD8 | 312.9K CAD8 | 195.8K CAD2 | |||||
| Total liabilities | 402.1K CAD10 | 314.2K CAD5 | 673.9K CAD6 | 1.2M CAD7 | 84.5K CAD8 | 604.9K CAD9 | 529.2K CAD2 | 330.8K CAD2 |
| Retained earnings | -30.2M CAD8 | -31.0M CAD9 | -31.7M CAD2 | -32.4M CAD2 | ||||
| Shareholders’ equity | 2.5M CAD6 | 886.0K CAD7 | -465.5K CAD8 | -724.0K CAD9 | 2.2M CAD2 | 2.0M CAD2 | 2.0M CAD2 | 2.0M CAD2 |
| Shares outstanding | 27.9M shares11 | 0 shares10 | 0 shares5 | 0 shares6 | 97.5M shares7 | 99.2M shares8 | 99.6M shares9 | 101.3M shares2 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.0M CAD5 | -1.4M CAD6 | -686.4K CAD7 | -1.2M CAD8 | -1.2M CAD9 | -437.8K CAD2 | 660.4K CAD2 | 1.0M CAD2 |
| Depreciation and amortization | 18.0K CAD9 | 631 CAD2 | 2.3K CAD2 | 3.1K CAD2 | ||||
| Capital spending | 3.8K CAD10 | 5.0K CAD10 | 105.4K CAD9 | 1.2M CAD2 | 1.0M CAD2 | 181.1K CAD2 | ||
| Free cash flow | -1.0M CAD | -1.4M CAD | -1.3M CAD | -1.6M CAD | -361.2K CAD | 823.5K CAD | ||
| Cash from investing | -140.4K CAD9 | -1.2M CAD2 | -1.0M CAD2 | -205.3K CAD2 | ||||
| Cash from financing | 3.1M CAD9 | 253.9K CAD2 | 42.5K CAD2 | 56.6K CAD2 |
What it owns
What Avricore Health Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | 656.4K CAD2 Dec 31, 2024 | 1.7M CAD2 Dec 31, 2023 | −61.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | 1.1M CAD2 Dec 31, 2024 | 276.6K CAD2 Dec 31, 2023 | +309.4% |
Inventory
Former names
Filings
45 filings to the SEC since October 2021: 4 annual reports, 41 other. The latest 20:
- Oct 13, 20266-K EDGAR
- Sep 17, 20266-K EDGAR
- Jul 13, 20266-K EDGAR
- Jun 11, 20266-K EDGAR
- May 11, 20266-K EDGAR
- Feb 17, 20266-K EDGAR
- Jan 12, 20266-K EDGAR
- Dec 10, 20256-K EDGAR
- Sep 15, 20256-K EDGAR
- Aug 8, 20256-K EDGAR
- Jul 11, 20256-K EDGAR
- Jun 16, 202520-F EDGAR
- Jun 5, 20256-K EDGAR
- May 20, 20256-K EDGAR
- Feb 6, 20256-K EDGAR
- Dec 5, 20246-K EDGAR
- Oct 7, 20246-K EDGAR
- Sep 6, 20246-K EDGAR
- Jul 9, 20246-K EDGAR
- Jun 20, 20246-K EDGAR
The 45 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How Avricore Health Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAvricore Health Inc.1
- CIK0001355736
- Filer statusNon-accelerated filer not an emerging growth company; a shell company4
- Incorporated inBritish Columbia, Canada4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address789 West Pender Street, Suite 810, Vancouver, A1 V6C 1H21
- Phone604-687-20381
- Shares outstanding101,289,664 shares as of Dec 31, 20244
- AuditorManning Elliott LLP, Vancouver, Canada PCAOB ID 1524; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMar 20, 20061
- Filings241 in all: 6-K (201), 20-F (20), UPLOAD (6), 20-F/A (5), CORRESP (5), NT 20-F (3), 20FR12G (1)1
- Latest filingsAnnual report (20-F) Jun 16, 2025
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11